Search
Levodopa
go.drugbank.com/drugs/DB01235ApprovedInvestigationalLevodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. … Once past the blood-brain barrier, levodopa is metabolized to dopamine and supplements the low endogenous levels of dopamine to treat symptoms of Parkinson's[Label].
Mixtures: MADOPAR 125 T, MADOPAR 125 TCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeLasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigationalLasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019. … [A187322,A187319] Selectivity for 5-HT<sub>1F</sub>, a lack of vasoconstrictive activity, and the ability to terminate migraines through neuronal inhibition has resulted in the creation of a new class
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeRaltegravir
go.drugbank.com/drugs/DB06817ApprovedInvestigationalFood and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. … Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S.
Categories: Antivirals used in combination for the treatment of HIV infectionsRivaroxaban
go.drugbank.com/drugs/DB06228ApprovedInvestigationalHowever there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. … Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary.
Ziprasidone
go.drugbank.com/drugs/DB00246ApprovedInvestigational[A180748] It can effectively reduce the rate and time of relapses in schizophrenia, and can be used to treat manic episodes in bipolar disorder although the mechanism of action is unknown. … [A180748] Although ziprasidone is classified as an atypical antipsychotic, it appears to have a lower incidence of metabolic adverse effects compared to other medications in the same class.[A190525]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeAmoxapine
go.drugbank.com/drugs/DB00543ApprovedThe antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. … Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeBordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)
go.drugbank.com/drugs/DB10991ApprovedInvestigationalthat infects the mucosal layers of the human respiratory tract. … Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) is a vaccine that is used in the prophylaxis of Pertussis (whooping cough), which is caused by a small Gram-negative coccobacillus
Mixtures: INFANRIX (TM) - IPV, PENTAXİM 0,5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇİN TOZ İÇEREN FLAKON VE SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETPhenoxypropazine
go.drugbank.com/drugs/DB09251ApprovedWithdrawnPhenoxypropazine is a non-selective and irreversible monoamine oxidase enzyme inhibitor (MAOI), belonging to the _hydrazine_ chemical class.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeParoxetine
go.drugbank.com/drugs/DB00715ApprovedInvestigational[T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. … [A31914] The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeOlmesartan
go.drugbank.com/drugs/DB00275ApprovedInvestigationalangiotensin I to angiotensin II through inhibition of the ACE enzyme. … However, this does not prevent the formation of all angiotensin II within the body.
Mixtures: OLMESARTAN E AMLODIPINA EG, OLMESARTAN E AMLODIPINA EGCategories: Agents Acting on the Renin-Angiotensin System